Fig. 3From: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancerA prognostic nomogram for predicting PFS of patients with metastatic breast cancer. PFS progression-free survival, HR hormone receptorBack to article page
